Flood Law Group Now Available to Investigate Claims Related to...
Flood Law Group announced today that it is now available to investigate claims related to complications from taking prescription Invega extended release tablets. Invega, also known by its generic name...(PRWeb May 07, 2014)Read the full story at http://www.prweb.com/releases/invega-complications/flood-law-group/prweb11809557.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - May 8, 2014 Category: Pharmaceuticals Source Type: news
Long-acting Paliperidone Safe, Effective for Dual PsychosisLong-acting Paliperidone Safe, Effective for Dual Psychosis
Switching patients with dual psychosis from other long-acting and oral antipsychotic medications to long-acting injectable paliperidone palmitate is safe and effective, a small study suggests. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 11, 2014 Category: Consumer Health News Tags: Psychiatry News Source Type: news
Janssen reports PALMFlexS trial results of schizophrenia drug Xeplion
Janssen Pharmaceutica has reported encouraging results from the PALMFlexS study, which demonstrated the efficacy, safety and tolerability of Xeplion (paliperidone palmitate) in patients with schizophrenia at various stages of the disease. (Source: Drug Development Technology)
Source: Drug Development Technology - December 2, 2013 Category: Pharmaceuticals Source Type: news
New Data Show Efficacy, Safety and Tolerability of Xeplion(R) in Patients with Schizophrenia at Various Stages of the Disease
PALMFlexS study better reflects Xeplion® use in everyday clinical practice compared to previous clinical trials
BEERSE, Belgium--(Healthcare Sales & Marketing Network)--Janssen Pharmaceutica NV has announced results of the PALMFlexS study during Th... BiopharmaceuticalsJanssen Pharmaceutica, Xeplion, paliperidone, Schizophrenia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 29, 2013 Category: Pharmaceuticals Source Type: news
J&J Agrees to Pay $2.2B to Resolve Criminal/Civil Allegations
Justice Department officials alleged that J&J used illegal marketing tactics and kickbacks to persuade physicians and pharmacists to prescribe Risperdal and Invega (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 5, 2013 Category: Pharmaceuticals Source Type: news
Johnson & Johnson to pay $2.2B in U.S. health care fraud settlement
Allegations include paying kickbacks to physicians, pharmacies to recommend and prescribe antipsychotic drugs Risperdal and Invega, and heart failure drug Natrecor (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - November 4, 2013 Category: Consumer Health News Source Type: news
Paliperidone palmitate: efficacy and cost effectiveness
Any treatment that offers even a small advantage in preventing relapse in schizophrenia must be clinically and economically advantageous. Paliperidone palmitate long-acting injection might be just such a treatment (Source: Pharmacy Europe)
Source: Pharmacy Europe - October 2, 2013 Category: Drugs & Pharmacology Authors: ebercott Tags: Featured Articles Source Type: news
Flexible-Dose Injectable Effective for Acute SchizophreniaFlexible-Dose Injectable Effective for Acute Schizophrenia
Flexible dosage of the injectable atypical antipsychotic paliperidone palmitate may be effective and well tolerated in patients with acute schizophrenia unsuccessfully treated with oral antipsychotics. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 11, 2013 Category: Consumer Health News Tags: Psychiatry News Source Type: news
Quick Facts About Invega - Paliperidone
Invega – generic name paliperidone – is an atypical antipsychotic approved for the treatment of schizophrenia and used off-label to combat acute mania in patients with bipolar disorder. It is derived from the active metabolite of Risperdal (risperidone). Here are a few important facts about this medication. (Source: About.com Bipolar Disorder)
Source: About.com Bipolar Disorder - June 15, 2013 Category: Psychiatry Authors: bipolar.guide at about.com Tags: health Source Type: news
